Stockscreener 앱 받기
12.69
3.00%
0.37
시간 외 거래:
12.69
전일 마감가:
$12.32
열려 있는:
$12.3
하루 거래량:
566.29K
Relative Volume:
0.26
시가총액:
$196.88M
수익:
$10.73M
순이익/손실:
$-455.74M
주가수익비율:
-3.5677
EPS:
-3.5569
순현금흐름:
$-502.70M
1주 성능:
-12.72%
1개월 성능:
-82.58%
6개월 성능:
-69.09%
1년 성능:
-59.99%
1일 변동 폭
$11.95
$12.87
1주일 범위
$11.95
$14.55
52주 변동 폭
$11.95
$73.06
어비디티 바이오사이언스 Stock (RNA) Company Profile
Compare RNA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNA
Atrium Therapeutics Inc
|
12.69 | 191.14M | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 개시 | Wells Fargo | Overweight |
| 2025-09-17 | 개시 | Roth Capital | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Bernstein | Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-06-11 | 개시 | Raymond James | Strong Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-20 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-09-24 | 개시 | Goldman | Buy |
| 2024-08-28 | 개시 | Barclays | Overweight |
| 2024-05-03 | 개시 | BofA Securities | Buy |
| 2024-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-05-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Strong Buy |
| 2021-09-07 | 개시 | Evercore ISI | Outperform |
| 2021-06-17 | 개시 | Needham | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | SVB Leerink | Outperform |
| 2020-07-07 | 개시 | Wells Fargo | Overweight |
모두보기
어비디티 바이오사이언스 주식(RNA)의 최신 뉴스
Stephanie Kenney Net Worth (2026) - GuruFocus
Novartis acquisition spin-off pioneers RNA therapeutics for the heart - Pharma Voice
Rocio Martin Hoyos Net Worth (2026) - GuruFocus
Brendan R. Winslow Net Worth (2026) - GuruFocus
Atrium Mortgage Investment (TSE:AI) Given a C$13.12 Price Target at Fundamental Research - Defense World
Stock List: Research Stocks from Around the World - GuruFocus
Atrium Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | RNA | US04965N1046 - marketscreener.com
Finance Watch: Market Struggles On Iran War, Jobs Data, Impacting Biopharma Stocks - Citeline News & Insights
Atrium Therapeutics Inc. (NASDAQ: RNA)Share Price and Research - intelligentinvestor.com.au
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - BioWorld MedTech
Rx Rundown: EveryOne Medicines, Atrium Therapeutics, Moderna and more - Medical Marketing and Media
RNA SEC FilingsAtrium Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Atrium Therapeutics Inc. share price - Capital.com
Trade Atrium Therapeutics Inc.RNA CFD - Capital.com
Atrium Tx launches with Avidity's RNA ticker and cardio assets - bioworld.com
Atrium Therapeutics, Inc. (RNA): An Insightful Analysis of a Biotech Challenger with a $2.28 Billion Market Cap - DirectorsTalk Interviews
Atrium Therapeutics, Inc.(NasdaqGS: RNA) added to NASDAQ Composite Index - marketscreener.com
Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions - MedCity News
Novartis completes $12 billion acquisition of Avidity Biosciences - Indian Pharma Post
RNA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Atrium Therapeutics Stock Pre-Market (-4.5%): Launch as Public Company Post-Spin-Off - Trefis
Avidity Biosciences (NASDAQ:RNA) Reaches New 12-Month LowHere's What Happened - MarketBeat
Q4 Earnings Estimate for CVE:DWS Issued By Atrium Research - Defense World
Novartis completes $12 billion Avidity Biosciences acquisition By Investing.com - Investing.com Canada
Atrium Arises From Novartis’s Avidity Buyout - Citeline News & Insights
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger - Finviz
Merger cashout for Avidity Biosciences (RNA) director Simona Skerjanec - Stock Titan
Avidity Biosciences (RNA) CMO options cashed out in $72 Novartis buyout - Stock Titan
Avidity Biosciences (RNA) CLO disposes stock, options in Novartis merger - Stock Titan
[Form 4] Avidity Biosciences, Inc. Insider Trading Activity - Stock Titan
Merger cash-out: Avidity Biosciences (RNA) officer’s options and shares disposed - Stock Titan
Novartis buyout: Avidity Biosciences (NASDAQ: RNA) director’s equity cashed out - Stock Titan
Avidity Biosciences (RNA) CTO equity disposed in $72 Novartis merger - Stock Titan
Avidity Biosciences shareholders approve merger with Novartis By Investing.com - Investing.com Australia
Novartis (NVS) Backs Atrium Therapeutics' Launch with $270M Funding - GuruFocus
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA - BioPharma Dive
Operating expenses (excl. COGS) of Avidity Biosciences, Inc. – NASDAQ:RNAM - TradingView
Avidity-Novartis deal spins out Atrium Therapeutics - The Pharma Letter
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates - Fierce Biotech
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week HighHere's What Happened - MarketBeat
Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates - marketscreener.com
Atrium Therapeutics Launches with $270M - Contract Pharma
Novartis completes acquisition of Avidity Biosciences - TipRanks
Avidity Biosciences Completes Merger and Plans Nasdaq Delisting - TipRanks
[POSASR] Avidity Biosciences, Inc. SEC Filing - Stock Titan
As Novartis deal closes, Avidity's rare heart disease spinout launches with $270M - Endpoints News
Novartis (NVS) Completes Acquisition of Avidity Biosciences - GuruFocus
Novartis Completes Acquisition of Avidity Biosciences - marketscreener.com
Novartis completes acquisition of Avidity Biosciences; shares to be delisted from Nasdaq - Investing.com
Novartis Closes $12 Billion Acquisition of Avidity Biosciences - marketscreener.com
Avidity Biosciences Ends ATM Sales Agreement With TD Securities Following Novartis Merger Close - TradingView
어비디티 바이오사이언스 (RNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
어비디티 바이오사이언스 주식 (RNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Jan 21 '26 |
Sale |
72.45 |
14,387 |
1,042,338 |
269,007 |
| Flanagan W. Michael | Chief Scientific Officer |
Jan 21 '26 |
Sale |
72.45 |
6,534 |
473,388 |
85,093 |
| MacLean Michael F | Chief Financial Officer |
Jan 21 '26 |
Sale |
72.45 |
4,542 |
329,068 |
59,290 |
| LEVIN ARTHUR A | Director |
Jan 21 '26 |
Sale |
72.45 |
1,758 |
127,367 |
16,562 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 21 '26 |
Sale |
72.45 |
2,929 |
212,206 |
113,938 |
| Boyce Sarah | President and CEO |
Jan 07 '26 |
Sale |
72.23 |
8,576 |
619,444 |
283,394 |
| Calderaro Charles III | Chief Technical Officer |
Jan 07 '26 |
Sale |
72.23 |
3,727 |
269,201 |
49,797 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 07 '26 |
Sale |
72.23 |
1,965 |
141,932 |
116,867 |
| Moriarty John B | Chief Legal Officer |
Jan 07 '26 |
Sale |
72.23 |
2,374 |
171,474 |
74,557 |
| MacLean Michael F | Chief Financial Officer |
Jan 07 '26 |
Sale |
72.23 |
1,974 |
142,582 |
63,832 |
1.20%
0.06%
자본화:
|
볼륨(24시간):